

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

**ACADEMY OF MANAGED CARE PHARMACY**

2. Address:

100 NORTH PITT STREET, #400, ALEXANDRIA, VA 22314

3. Principal place of business (if different from line 2):

4. Contact Name: WILLIAM HERMELIN

Telephone: 7036838416

E-mail (optional): bhermelin@amcp.org

Senate ID #: 48793-12

House ID #:

7. Client Name:  Self

### TYPE OF REPORT

8. Year 2005 Midyear (January 1 - June 30):  **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report:  => Termination Date: \_\_\_\_\_ 11. No Lobbying Activity:

### INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

#### 12. Lobbying Firms

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more:  => Income (nearest \$20,000): \_\_\_\_\_

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

#### 13. Organizations

**EXPENSES** relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more:  => Expenses (nearest \$20,000): 100,000.00

#### 14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

**Method A.** Reporting amounts using LDA definitions only

**Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

**Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: ACADEMY OF MANAGED CARE PHARMACY Client Name: Self

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

Wired for Health Care Quality Act (S1418) Pharmaceutical Market Access and Drug Safety Act (S109/S334/HR328/HR700)  
"Conscience Clause" legislation (HR1539) Pharmacy Benefit Manager Transparency Act (HR1669) Community Pharmacy Fairness Act (HR 1671) Patient Safety and Quality Improvement Act (S544/HR3205) Fair Access to Clinical Trials Act (S470/HR3196) National All Schedules Prescription Electronic Reporting Act (S518/HR1132) FDA Improvement Act (S930/HR2090)

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: HERMELIN, WILLIAM M.

Covered Official Position (if applicable): N/A

Name: JAMES, MELISSA

Covered Official Position (if applicable): N/A

Name: MILLER, CYNTHIA (CINDY)

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ACADEMY OF MANAGED CARE PHARMACY Client Name: Self

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

Medicare Prescription Drug Savings and Choice Act (HR752) Medicare Prescription Drug Improvement Act (HR1626) Prescription Drug Price Fairness Act (HR2200) Preserving Medicare for All Act (HR2487) Medicare Prescription Drug Price Negotiation (HR 2685) Rescinds current MMA exclusion of benzodiazepines from coverage (HR3151) Allows HHS negotiation with manufacturers regarding drug price (HRes 267/S183) Meeting Our Responsibility to Medicare Beneficiaries Act (S123) Medicare Enhancements for Needed Drugs (S239) Medicare Prescription Drug Savings and Choice Act (S345/S873) Medicare Prescription Drug Price Reduction Act (S445) Medicare Value Purchasing Act (S1356) Budget Resolutions re: Medicare/Medicaid (S.Con.Res. 18/H. Con.Res.95) Labor/HHS Appropriations (HR3010) Medicare's Equitable Drugs for Seniors Act (HR376) Prescription Drug Affordability Act (HR563)

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: HERMELIN, WILLIAM M.

Covered Official Position (if applicable): N/A

Name: JAMES, MELISSA

Covered Official Position (if applicable): N/A

Name: MILLER, CYNTHIA (CINDY)

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: ACADEMY OF MANAGED CARE PHARMACY Client Name: Self

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: PHA (one per page)

16. Specific lobbying issues:

Access to Generic Drugs; Prescription Drug Importation; Counterfeit Drugs

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: HERMELIN, WILLIAM M.

Covered Official Position (if applicable): N/A

Name: JAMES, MELISSA

Covered Official Position (if applicable): N/A

Name: MILLER, CYNTHIA (CINDY)

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Mar 16, 2007

Printed Name and Title: WILLIAM HERMELIN, DIRECTOR OF GOVERNMENT RELATIONS -

**Information Update Page:**

**Complete ONLY where registration information has changed.**

**LOBBYIST UPDATE**

**23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client**

**ISSUE UPDATE**

**24. General lobbying issues previously reported that NO LONGER pertain**

**AFFILIATED ORGANIZATIONS**

**25. Add the following organization(s)**

**26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client**

**FOREIGN ENTITIES**

**27. Add the following foreign entities**

**28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization**

Signature: ON FILE      Date: Mar 16, 2007

Printed Name and Title: -